Time saving

£100

Plus:

Inside this edition:

gallerySee a showcase of agency ads atwww.pmlive.com/thegallery 43

of Advertising, Branding, Creative and Digital Agencies in Healthcare

© PM

Group 2010. A

ll rights reserved.

http://jobs.pmlive.com

Tara Lovegrove01372 414242 [email protected]

*Source Google Analytics: December 2013

Easier

Better

Time saving

More fl exible

JOBSPharma marketing & healthcare advertising jobs©

PMG

roup 2010. All rights reserved.

As we know too well, the worlds of advertising, branding, creative and digital in healthcare never sit still, and yet more regulatory changes are forcing agencies and pharma companies to react and continue to evolve.

First off, long-awaited guidance from the US FDA on social media is the subject of our introduction analysis, where PMGroup editorial director Dominic Tyer gives his take on what the guidelines mean for the industry. And in Europe, changes to the EFPIA’s Code of Practice are having a national impact, as code expert Joan Barnard discusses in ‘The changing regulatory environment’. Two major areas of growth in life sciences right now are biosimilar copies of biologic drugs and orphan drugs for rare diseases. This issue features analysis of the impact on marketers for both areas, with articles from Reg Manser and Whitney Andrews and Elizabeth Chambers.

Adherence to medicines remains an ongoing problem in healthcare and David Hunt discusses how building an effective user experience through digital technology can help in the battle. Elsewhere, story-telling is a compelling way to communicate a message, but Nick Dutnall argues that companies must first have the authority to publish.

We also bring you the results of PMGroup’s Digital Futures survey, which asked marketers what digital issues were the most important for them going forward. And finally, our 10 Ways guide tells you all you need to know on making the most of the PMHub – the online resource for service companies working in pharma.

fast forward

Thomas Meek - PMGroup [email protected]

Contents

www.pmlive.com/thedirectory 3the directory of advertising, branding, creative and digital agencies in healthcare 43

£100

Plus:

Inside this edition:

gallerySee a showcase of agency ads atwww.pmlive.com/thegallery 43


Dx43_Cover_NewImages.indd 1

digitaleditionView The Directory online at: www.pmlive.com/thedirectory

THE TEAM

Managing directorPMGroup editor Business development manager Commercial director Production manager Art editorDesignerEditorial director Creative director Production director

Published by:

Printed by:

Gallery thumbnails (left-right): Havas Lynx, Langland, Life Healthcare Communications,Life Healthcare Communications

@DxHealthLiVE

INDEXES

A-Z PROFILES

FEATURES

UPDATES© PM

Group 2010. A

ll rights reserved.

PME is packed full of informative and stimulating content · Interviews with thought leaders · In-depth articles on innovation and R&D· Market access issues by geography and therapy area· The latest in digital thinkingand much, much more...

To Find out more visit www.pmlive.com/pme

© PM

Group 2010. A

ll rights reserved.

VOLUME 43

INTRODUCTION

the directory of advertising, branding, creative and digital agencies in healthcare 43 www.pmlive.com/thedirectory 5

ASOCIAL MEDIA RECOMMENDATIONS

FDA example

FDA example

FDA example

REAL-TIME INFORMATION

The AuthorDominic Tyer is editorial director of PMGroup

What new guidance means for pharma’s digital engagement

THE US FDA AND SOCIAL MEDIA

© PM

Group 2010. A

ll rights reserved.

the directory of advertising, branding, creative and digital agencies in healthcare 43www.pmlive.com/thedirectory6

APPO

INTM

ENTS

Recent moves in the world of healthcare advertising, branding, creative and digital

APPOINTMENTS

Michael Leis

Michael Leis

Mark Farnworth

Mark Farnworth

The Directory

Stephen Davies

Stephen Davies

John Grime

John Grime

Erik Hawkinson Erik Hawkinson

Emily Wigginton, Eleanor Nixon and Alice Kaberry

Emily Wigginton

Eleanor Nixon

Alice Kaberry

© PM

Group 2010. A

ll rights reserved.

APPOINTMENTS


Jenny Adamson, Andrei Neagu and Adam Richardson

Jenny Adamson Andrei Neagu Adam Richardson

Peter Fontana, Richard O’Connor and Andy Chapman

Peter Fontana Richard O’Connor Andy Chapman

Amar Urkehar

Amar Urkehar

Paul HaleyPaul Haley

Bettina Weber

Bettina Weber

Liam EnglishLiam English

© PM

Group 2010. A

ll rights reserved.


THE

REGU

LATO

RYEN

VIRO

NMEN

T

© PM

Group 2010. A

ll rights reserved.

THE REGULATORYENVIRONM

ENT


EFPIA Code demands that industry declares all transfers of value to healthcare professionals and healthcare organisations

This update must be refl ected across EU nation codes, including ABPI’s Code of Practice

ABPI Code now requires companies producing patient-focused material for medicines to include information on reporting of adverse events and a black triangle symbol

Key Code updatesT

“You will be profoundly affected by the movement towards full transparency”

The AuthorDr Joan Barnard is managing director of consulting fi rm Code in Practice. Her books, The Code in Practice and The Code in the Field, have been updated in line with the 2014 ABPI Code. Contact her on email via [email protected] or visit www.codeinpractice.co.uk

© PM

Group 2010. A

ll rights reserved.


BIOS

IMIL

ARS

AND

BRAN

DING


BIOS

IMIL

ARS

AND

BRAN

DING

Creating a whole new brand identity for replicated biologics

© PM

Group 2010. A

ll rights reserved.

BIOSIMILARS

AND BRANDING


NOTHING COMPARES

The AuthorReg Manser

Martin New

BSAME SONG, DIFFERENT MEANING?

RESPECT DUE

THERE’S TOO MUCH CONFUSION

BIOSIMILARS

AND BRANDING


Fast track

Find out more atwww.pmlive.com/biosimilars

© PM

Group 2010. A

ll rights reserved.


MAR

KETI

NGIN

RAR

E DI

SEAS

ES

Orphan drugs require a more innovative, insightful take on branding strategy

A

Rare diseases

© PM

Group 2010. A

ll rights reserved.

MARKETING

IN RARE DISEASES


The AuthorsWhitney Andrews is senior account director and Elizabeth Chambers is group account director, Langland. Email [email protected] or [email protected]

Small patient numbers and target customers mean traditional marketing techniques are often not viable for orphan drugs

Innovation, creativity and authenticity are key in communications surrounding orphan conditions

First-hand insight and feedback are necessary to understand the experience, needs and wants of patients, carers and healthcare professionals

For more on rare diseases and orphan drugs visit www.pmlive.com/rarediseases

Fast track

Rare disease facts

© PM

Group 2010. A

ll rights reserved.


IMPR

OVIN

G AD

HERE

NCE

XU DRIVING ADHERENCE: ARE YOU PUSHING THE RIGHT BUTTONS?

© PM

Group 2010. A

ll rights reserved.

IMPROVING

ADHERENCE


principles of motivation to encourage positive changes in behaviour: from loyalty cards to LinkedIn profiles that rate the ‘strength’ of our online presence to encourage us to provide more information. One of the greatest exponents of such methods is Nike, who utilises a range of ‘gamification’ techniques in its training and fitness apps: badges and other indicators of progress, meaningful rewards, social engagement with other users, all wrapped-up in intuitive operating experiences.

Modern digital technologies have a number of properties that make them a particularly effective facilitator for behavioural change. Their pervading presence in everyday life has caused us to become very quick adopters of a wide range of principles and functions. ‘Like’ buttons, pinching and zooming hand gestures, and hash-tagging are now as engrained in our unthinking behavioural patterns as more traditional habits. The best way to encourage adherent behaviours is to link them to existing habits, and so by hosting interventions that encourage adherence within the network of deeply engrained digital behaviours, we increase the chance of their adoption.

INTERACTIVITYThe interactive power of many modern platforms allows us to actively involve participants causing messages to resonate with great strength. Interaction can instil a deeper understanding of the principles you’re conveying, thus empowering patients to feel more confident about adopting them in everyday life. ClickHealth’s Bronkie the Bronchiasaurus was a Nintendo video game designed to help children with asthma manage their condition. The game required players to complete asthma management tasks similar to those for humans. The

“Interaction can instil a deeper understanding”

• Adherence has always been one of the largest obstacles in healthcare

• Consider and understand the behaviours that lead to non-adherence to develop a good user experience

• Create messages that resonate by involving patients through digital technologies

Fast track

results were highly impressive. Children who played for as little as 30 minutes reported increased efficacy, significantly out-performing a test group who were shown an informative film instead of playing the game. What’s more, the increase proved to be lasting, with the improved efficacy maintained long after the study session had occurred. The implication is that it was the interactive nature that was crucial; by actively engaging the children and allowing them to rehearse the behaviours, the game gave them the confidence to apply these practices in a real-life setting.

As more-or-less constant companions in our lives, mobile devices are in a unique position to encourage adherence among patients. This is in part due to their obvious convenience, but also their ability to store and detect data relating to a range of different factors (such as our location, the time of day, our schedule, who we’re with etc) and utilise this data to offer timely prompts that influence our behaviour. The sheer quantity of personal data potentially available to mobile devices means that they can very easily ‘get to know’ a huge number of personal habits. When combined with methods of persuasion and interaction, this kind of ‘digital empathy’ offers some incredible potential to deliver timely disruptive behaviours that encourage adherence.

As Benjamin Franklin said: “Tell me and I forget. Teach me and I remember. Involve me and I learn.”

The AuthorDavid Hunt is chief executive of Havas Lynx. He can be contacted at [email protected] further reading see the Havas Lynx white paper ‘Pushing the right buttons, a guide to unlocking better outcomes in healthcare with UX’.

User experience (UX) is one of the main buzzwords in digital communications. And adherence is healthcare’s eternal

ambition. But are they linked?The key to good UX is understanding

a user’s habits and behaviours and creating interventions that fit around these behaviours to help him or her reach his or her goals. Replace ‘user’ with ‘patient’ and that last statement could equally be referencing adherence - one of the largest obstacles in healthcare for one simple reason: it’s hard. Recovery programmes can be long and arduous; they require routine behaviours that are boring and unpleasant and they often provide little indication of progression or success. The pressure on so many areas of our lives is eased by thoughtful, user-centric design and we need to take the same approach to adherence.

A HOLISTIC VIEWThere’s rightly been a lot of noise about pharma’s increased role in maintaining adherence and the need to go ‘beyond the pill’. Our response must be more than lip service. Gone are the days when a hastily put together advice booklet was enough. Pharma is under the microscope more than ever; healthcare providers don’t want expensive patented drugs that will drain their purses, they want effective and economical treatment systems. They want long-lasting improvements in quality of life for patients and that reduce the costly burden of care. To achieve this we need to take a holistic view of patient pathways, supporting them and the stakeholders throughout this pathway. The quality of this support is paramount, in both its strategy and execution, and that’s where the principles of UX come in.

Information alone isn’t enough. You can tell patients that something is good for them but that doesn’t mean they’ll do it. When they’re isolated and alone, good advice that was given to them weeks ago can seem irrelevant. We need to provide motivation as well as information. We need to consider the behaviours that lead to non-adherence and help patients to change these behaviours. Our daily lives are full of products that utilise

© PM

Group 2010. A

ll rights reserved.


THE

AUTH

ORIT

Y T

O PU

BLIS

H

A brand must be a story-doer as well as a storyteller

THE AUTHORITYTO PUBLISH

© PM

Group 2010. A

ll rights reserved.

THE AUTHORITY TO PUBLISH


THE MORAL OF THIS STORY?

The AuthorNick Dutnall is head of health at Aesop. Email him at [email protected]

through its actions

Fast TrackB

“The stories a brand tells must reflect a truth”

Advertising campaigns (L-R): Coke - Live like Grandpa, Coke - Vending Machine, Guinness - Sapeurs

© PM

Group 2010. A

ll rights reserved.


DIGI

TAL

DIRE

CTIO

NS

Following our online survey on digital marketing, what does the industry expect in 2014?

What would you like to make more use of in 2014?

What social media channelwill you fi nd most valuable

What will your company focus on in 2014?

What social media channel will be most important for your company?

For all the chatter that’s been heard over the years about how pharmaceutical companies just don’t

‘get’ digital marketing, one of the most striking results from the Digital Futures 2014 survey was how well-aligned company and individual priorities seem to be.

The online survey, run by The Directory publisher PMGroup in association with Havas Lynx, heard the views of nearly 250 people working in and for the pharma industry, including representatives from advertising, branding, creative and digital agencies. Among the questions were those that asked what aspects of digital marketing individuals would like to make more use of in 2014 and which ones they thought their company would focus on over the next 12 months.

Before analysing the responses I had expected to fi nd individuals chomping at the bit to launch ‘gamifi cation’ or ‘quantifi ed self’ initiatives, along the lines of the sometimes innovative (but sometimes just buzzword-friendly) work that features in the Digital Intelligence blog at PMLiVE.com. And I did wonder if respondents would witheringly tell us that their company’s top priority would be to build yet more product websites in 2014.

Instead, the top answers in both questions included multi-channel marketing, a well-worn phrase with a solid kernel of truth at its heart. What company wouldn’t want to better integrate its different marketing efforts, despite the complexity of bringing all the potential strands of digital marketing activity alongside the more traditional elements of the marketing mix? Multi-channel marketing’s high showing in the survey also suggests pharma is moving

© PM

Group 2010. A

ll rights reserved.

DIGITALDIRECTIONS


and strong approach to strategy. As JHI partner Marco Mohwinckel said

at the Health 2.0 Europe event last year: “We really want to transform J&J from being product-centric to being a broader healthcare company.”J&J may have topped the company

category but it wasn’t a runaway success. Hard on their heels was Boehringer Ingelheim, praised for its “heritage in digital and social media and lack of internal restrictions”.

But perhaps the last word should go to the respondent who, when asked ‘What areas of digital marketing would you like to make better use of in 2014?’, answered:

“Anything that’s useful and not just digital for the sake of being trendy.”

The AuthorDominic Tyer is editorial director of PMGroup.

from experimenting with digital marketing’s more recent developments, like mobile and social, as ‘digital’ is evermore embedded within pharma marketing.

PRIORITIES AND SOCIAL MEDIAThe alignment between the digital

marketing elements survey respondents wanted to make more use of in 2014 and those they expected their company to focus on didn’t end there. Four of the top fi ve answers crossed over (see table), with only social media use (respondents) and e-details (companies) not matching up. The only difference to note at this end of the scale was the extent to which respondents and their companies were expected to prioritise the different elements - respondents, for example, gave a higher weighting to mobile apps, which they ranked joint fi rst as something they’d like to make more use of this year.

When it came to the social media channels that respondents thought both they and their company would prioritise in 2014, there was absolute agreement about the most important channels to use. In both cases healthcare professional networks came out top, beating open social networks like Twitter, LinkedIn and Facebook. Blogging, always a more selective activity for pharma, nevertheless was still considered a core social media activity, and a top fi ve priority for pharma in 2014.

Online physician networks have seen continuous and signifi cant growth in recent years and lately there has been expansion among existing players like the M3 Group, whose networks includes Doctors.net.uk, and new entrants such as Cegedim Relationship Management’s Docnet. In addition to being ranked the top industry social media channel, online healthcare professional networks were also placed highly when it came to the digital marketing tools people would like to make more use of this year.

Less important to the respondents of our survey were YouTube or Vimeo, though, as Roche’s engaging Drawn To Science series shows, pharma videos can sometimes rise above industry view rates that often remain low. Below YouTube in the estimation of our respondents were visually-inclined networks like Pinterest and Instagram.

THE STRATEGY CHALLENGEThere was a clear answer from respondents to our survey when asked what they felt the industry’s biggest challenge in digital marketing this year would be. For a third of them the issue that they expect to loom the largest in 2014 is strategy, or, more accurately, unclear strategy. There’s advice on planning the big thinking behind your use of digital marketing on The Directory’s online home -www.pmlive.com - in the online Digital Handbook, and it counsels to consider last the digital tools or websites you will use and start instead with identifying internal stakeholders.

On its own, gaining internal buy-in for digital marketing remains a signifi cant challenge according to our survey, whose respondents said it would be pharma’s third biggest challenge in 2014. Internal buy-in bookended two forms of a familiar industry bugbear - rules, with overly-restrictive external regulations cited by 21 per cent of our survey, and working within internal rules suggested as this year’s pre-eminent challenge for pharma by 17 per cent of respondents.

GREAT THINGS EXPECTED OF J&JThe company expected to make best use of digital in 2014, according to our survey, is Johnson & Johnson, whose Janssen division is often at the forefront of digital marketing. From its groundbreaking use of social media in the UK to its European Digital Health Masterclass Challenge, the fi rm has a pedigree of innovation. J&J is also able to draw on its strengths in consumer marketing. As one respondent commented:

“Their devices are marketed in areas that are less encumbered with restrictive regulation and internal fear of ‘getting it wrong’.”

Much of the company’s digital innovation within the pharma space comes from Janssen Healthcare Innovation (JHI), an entrepreneurial team within Janssen’s R&D arm. The ‘master brand’ for JHI’s initiatives is Care4Today, which so far encompasses a digital adherence platform and heart health, orthopaedic and mental health initiatives Our respondents also noted J&J is “well established in this space” and highlighted its “proven capabilities”, “great culture”

The survey:

Which company will be best at digital marketing in 2014?

Johnson & Johnson

Boehringer Ingelheim

Pfi zer Novartis Sanofi

© PM

Group 2010. A

ll rights reserved.


PMHU

B

10 Ways for agencies to maximise their online profile

MAKE THE MOST OF THE PMHUB

W1. WHO ARE YOU?

2. WHAT DO YOU DO?

3. AREAS OF EXPERTISE & CLIENTS

4. TEAM & CULTURE

The Directory

Areas of expertise: CDM London details all the therapy areas it has experience in

Awards: Pan showcases its awards haul, including several from PMEA

© PM

Group 2010. A

ll rights reserved.

PMHUB


5. THOUGHT LEADERSHIP –WHITE PAPERS, PRESS RELEASES

6. VIDEO

7. SOCIAL MEDIA

8. AWARDS

9. TESTIMONIALS

10. UPDATES

Visit the PMHub at www.pmlive.com/pmhub For more information on the PMHubemail [email protected]

Video: Hanson Zandi promotes a video offering tips on iPad use and more

White papers and resources: Havas Lynx has plenty of useful white papers for the pharma marketer

Press releases: Life posts updates on key business developments

© PM

Group 2010. A

ll rights reserved.

getting the best out of

agencyprofi les

24-25 bmore creative

26-27 CDM London

28-29 Dark Horse Agency

30-31 Dice

32-33 H4B London

34-35 Halesway

36-37 Hanson Zandi

38-39 Havas Life Medicom

40-41 HAVAS LYNX

42-43 inVentiv Health

Communications

44-45 Langland

46-47 Life

48-49 MJL

50-51 PAN

52-53 Publicis Life Brands

Resolute

54-55 Seven Stones

56-57 Swordfi sh Advertising

go to the links at www.pmlive.com/thedirectory to view online or get the app


© PM

Group 2010. A

ll rights reserved.

YOUR AGENCIES IN HEALTHCARE – NOW AVAILABLE 24/7As well as in its printed form, you can access The Directory’s agency profi les in the digital edition at www.pmlive.com/thedirectory and by downloading the iPhone app from the App Store (simply search for ‘The Directory’). In the offi ce or not, it’s now even easier to refer to the latest agency profi les here in this edition.

FROM REQUESTS-FOR-INFORMATION TO MAKING CONTACTThe agency profi les in this section give you a closer look at the networks and the independents, their updated client and product lists, their specifi c strengths and expertise, and their countries of operation. Whether step one of collecting RFI or simply refreshing your recall of the agency specialists working in pharma and healthcare, The Directory will fi t your purpose. Once you’ve found what you’re looking for, we have the details of how to make initial contact.

thedirectory – in print, in digital edition… and on the App Store

go to the links at www.pmlive.com/thedirectory to view online or get the app

agencyprofiles

24-57


© PM

Group 2010. A

ll rights reserved.

RESPONSIVE WEB DESIGN

OUR SECRET IS OUR INNOVATION...

[email protected]

Innovation at bmore comes through our ability to see how digital technology is advancing, realising how this creates opportunities for our clients and taking advantage of these.

We provide solutions that really do create impact and make a difference to how you engage with your customers.

We are at the forefront of exciting technologies like gesture control and augmented reality.

& GESTURE CONTROL

TOUCHSCREEN

BRAND DESIGN

ON LOCATION IN HOUSE

HD 4KFILMING

&

+

AUGMENTEDREALITYGAMIFICATION

&

3D ANIMATION

3D PRINTING

& MOTIONGRAPHICS

CO UK

SMART PHONE & TABLET SOLUTIONS

30%70% OF WHAT WE DO

IS DIGITAL

OF WHAT WE DO IS TRADITIONAL

Set us a challenge, and see how we can bmore innovative for you.

© PM

Group 2010. A

ll rights reserved.

25

PROFILEBM

ORE CREATIVE

the directory of advertising, branding, creative and digital agencies in healthcare 43 www.pmlive.com/thedirectory

New business contacts

Head Offi ce:

London offi ce:

Telephone

Email

Website

Associated membership

The team

Date established

Corporate status

Total annual billings (Jan-Dec) 2013

Total annual healthcare billings(Jan-Dec 2013)

Number of staff

Number of staff working on healthcare accounts

Geographical status

Countries of operation

Method of remuneration

AGENCY INFORMATION

PORTFOLIO OF OPPORTUNITIES

P

Mobile First

Responsive DesignT

Content Marketing

EXPERTISE AND SERVICES

Abbott

AbbVie

Allergan

Baxter

Britannia

Derma UK

Ferring Pharmaceuticals

Galderma UK

Gilead

Idis

Lilly

MSD

Novartis

Penn Pharma

ProStrakan

Shire

Takeda

CLIENTS

BMORE CREATIVEPROFILE

FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.

Cures headaches.Improves sleep.

Encourages growth.

COMEGROWWITH US

Shouldn’t your new brand be competing with the big boys? Shouldn’t your highly efficacious brand be better known?

Shouldn’t your established brand be pushing for greater market share?

Many marketers have similar concerns about their brands, so why not discuss the right treatment with the nice

people here at CDM London.

We’ve been putting growth at the heart of what we do for nearly thirty years; after all, not all our big famous clients

have always been big famous clients.

To find out what we can do for your brand, call Phil Bartlett on 020 8735 8194.

© PM

Group 2010. A

ll rights reserved.

27

PROFILECDM

LONDON


New business contact

Address

Telephone

Email

Website


Associated companies

The team

Number of staff


Geographical status



AGENCY INFORMATION


CLIENTS

CDM LONDONPROFILE

Almirall

Amgen

Baxter

Bayer

BMS

Gedeon Richter

Novartis

Novo Nordisk

Pfizer

Roche

Account Management & Brand Planning:

Creative Strategy:

Multichannel Strategy:

Medical & Scientific Affairs:

Interactive Services:

Relationship Marketing:


© PM

Group 2010. A

ll rights reserved.

A good move this year

www.darkhorseagency.com

© PM

Group 2010. A

ll rights reserved.

PROFILE DARK HORSE AGENCY



Address

Telephone

Fax

Email

Website

The team

Established

Status

Number of staff


Geographical status



AWARDS

AGENCY INFORMATION


P

M

P

P

EXPERTISE AND SERVICESAbbott

Actelion

Alexion

Allergan

Bayer


BPL

Daniels Healthcare

June Medical

Malvern

Mitovie

CLIENTS

DARK HORSE AGENCY

Experience you can trust, Service you can depend on.

PROFILE

© PM

Group 2010. A

ll rights reserved.

Loaded in your favour

Creative thinking with substance

© PM

Group 2010. A

ll rights reserved.

31

PROFILE DICE



Address

Telephone

Email

Website


Established

Corporate status

Number of staff


Geographical status



PM Society

AWARDS

AGENCY INFORMATION


Actelion

Biogen Idec

Bridge to Life

Dreamskin

GSK

Immatics

Roche Diagnostics

CLIENTS PRODUCTS

DICEPROFILE


FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.

Creativity. Collaboration. Vision. And that’s just off the top of our heads.

ee what’s on our minds.SLONDON

GOOD CHEMISTRY

Medical Director

Production Manager

Editorial Director

Art DirectorManaging Director

StrategicPlanner

CopywriterAccount Manager

Digital Designer

© PM

Group 2010. A

ll rights reserved.

33

PROFILEH4B LONDON

the directory of advertising, branding, creative and digital agencies in healthcare 43 www.thedirectorylive.com


Address

Telephone

Email

Website

The team


Date established

Status

Number of staff


Geographical status



AGENCY INFORMATION


Strategic planning and consultancy

M

Campaign creation

G

Advertising and promotion

O

Medical communications and education

M

Digital

O

G


H4B LONDONPROFILE

Bayer EMEA

Bristol-Myers Squibb

EUSA Pharma


Janssen EMEA

Lundbeck

Merck Serono

sanofi

Shire

CLIENTS

FOLLOW US AT LONDONGOOD

CHEMISTRY

© PM

Group 2010. A

ll rights reserved.

Digital. Traditional. Inspirational.

Bring together the best in digital and traditional media

by putting your campaign in expert hands.

Find out more at www.halesway.co.uk

or call Niki Crossley on +44 (0)1264 339955.

© PM

Group 2010. A

ll rights reserved.

35

PROFILE HALESW

AY



Address

Telephone

Fax

Email

Website


The team

Established

Status

Number of staff



PM Society Advertising Awards

The Rx Club (New York) Awards

PMEA

OTC Marketing Awards

SMaRT Awards

W3 Awards

Web Health Awards

Davey Awards

AWARDS

AGENCY INFORMATION



Abbott Diabetes Care

Abbott Vascular

Alcon

Baxter Healthcare


Hospira

Mallinckrodt

Metrasens

MSD

Novartis

Owen Mumford

Reckitt Benckiser

Smith & Nephew

Takeda

CLIENTS PRODUCTS

HALESWAYPROFILE

FOLLOW US AT

EU

© PM

Group 2010. A

ll rights reserved.

HCPs have awarded our work for the second year running.So if you need to engage this audience, just call.

Blue Man by Hanson Zandi for Sirtex PM Awards 2013

© PM

Group 2010. A

ll rights reserved.

37

PROFILE HANSON ZANDI



Address

Telephone

Fax

Website

Established


Number of staff working on healthcare accounts10

Geographical status



AGENCY INFORMATION



Allergy Therapeutics

CSL Behring

ETHICON UK & Canada

ETHICON GYNECARE

Internis

Novo Nordisk

Orphan Europe

Ortho Clinical Diagnostics

Pfizer

Sage Healthcare

Sanofi Merial

Sealed Air

Sirtex Global and Europe

Smiths Medical Europe

CLIENTS PRODUCTS

HANSON ZANDI WE’LL LET YOU BE THE JUDGE

FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.

We understand that a good agency-client relationship is the cornerstone to producing exceptional, mould-breaking communications. That’s why, before we do anything else, we listen to our clients – to find out their goals and ambitions.

Then, once we’re on the same page, we pull out all the stops to reach, and exceed, their targets. Always with smiles on our faces. It really is that simple. And it tastes a lot better for everyone.

Appointing a communications agency can leave you feeling like you’ve swallowed this

It doesn’t have to

© PM

Group 2010. A

ll rights reserved.

39

PROFILE HAVAS LIFE M

EDICOM



Address

Telephone

Fax

Email

Website

The team

Date established

Corporate status


Total annual healthcare billings (Jan–Dec 2012)

Number of staff


Geographical status


AGENCY INFORMATION



CLIENTS

HAVAS LIFE MEDICOMPROFILE

PMEA

PM Society Awards

PharmaTimes Awards

Communiqué Awards

AWARDS

FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.

POSITIVE EFFECTS ON THE WORLD

We strive to make things better not just different, connecting professionals to patients with the knowledge, tools and services they need to achieve better outcomes.

We pride ourselves on meaningful innovation, we recognise that breakthroughs are not a matter of using a device or service first. They are born in thought and created through the application of knowledge for a helpful purpose.

Our portfolio of work brims with instances where we have successfully identified an opportunity to utilise a message, service or technology thoughtfully to improve a patient’s life and a brand’s success. It’s why we have won over 50 awards globally and why we have longstanding partnerships with our clients.

Our passion and intention is to bring about a change in healthcare. Change that transforms outcomes for patients, professionals and brands. Helpful change.

Developing brands and building relationships, combining insight, ideas and innovation

Medical education and scientific exchange, with clinical expertise, ethics and imagination

Software solutions for healthcare; an engine for effective change

www.havaslynx.com

© PM

Group 2010. A

ll rights reserved.

41

PROFILE HAVAS LYNX


FOLLOW US AT


Address

Telephone

Fax

Email

Website

The team

Established

Corporate status


Number of staff


Geographical status



AWARDS

HAVAS LYNX

HAVAS LYNX MEDICAL

HAVAS HEALTH SOFTWARE


AGENCY INFORMATION


AbbVie Alexion AllerganAlmirallAstellasAstraZenecaBayerBMSDaiichi SankyoEisai GrünenthalGSKJanssenKowa

LillyLundbeckMartindaleMedtronicMenariniMerck SeronoNappNovartisNovo NordiskRocheSanofiShireSiemensUCB

CLIENTS

HAVAS LYNXPROFILE

© PM

Group 2010. A

ll rights reserved.

If you’re ready to work as ONE, visit: http://ihce.inventivhealth.com

Done As One

© PM

Group 2010. A

ll rights reserved.

43

PROFILEINVENTIV HEALTH COM

MUNICATIONS



Address

Telephone

Fax

Email

Website


The team

Established

Associated Companies

Number of staff


Geographical status



AGENCY INFORMATION

INVENTIV HEALTH COMMUNICATIONSPROFILE


AWARDS

The Rx Club Awards

IPA Best of Health

Comprix Awards

GWA Heathcare Awards

Aspid Awards

Communiqué Awards

Holmes Report

OTC Marketing Awards

AbbVieActelionAllerganAstellasBayerBMS Boehringer IngelheimCSL BehringDaiichi SankyoEdwards Lifescience ElancoGE HealthcareGileadGrünenthalGSK

IpsenJanssen-CilagJohnson & JohnsonLillyMerck/MSDMerck SeronoNovartisNovo NordiskNutriciaPfi zerReckitt BenckiserRocheSanofi ShireSigma Tau

CLIENTS


FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.

WE LOVE WHAT WE DO AND WE THINK IT SHOWS

1. BAYER: Press advertising 2. CISCRP: Website 3. IDIS: Integrated campaign 4. BLISS: Awareness-raising animation 5. INC Research: Integrated campaign

5

3

Scan here to watch the fi lm

Scan here to view the site

For MS patients forced to rely on family and carers for essential tasks, the true cost of spasticity is their independence.

By reducing muscle spasm and stiffness, Sativex signifi cantly improves symptoms of moderate and severe MS spasticity

compared with placebo,1 giving back some priceless self-reliance from just £5.56 a day.*2

W H A T ’ S T H E T R U E C O S T O F M S S P A S T I C I T Y ?

* based on a price of £3752 for three 90-spray vials3 and a median dosage of 4 sprays per day4 Date of preparation: October 2012 Job code: L.GB.10.2012.0713

INDEPENDENT THINKING

For MS patients forced to rely on family and carers for essential tasks, the true cost of spasticity is their independence.

By reducing muscle spasm and stiffness, Sativex signifi cantly improves symptoms of moderate and severe MS spasticity

compared with placebo,1 giving back some priceless self-reliance from just £5.56 a day.*2

W H A T ’ S T H E T R U E C O S T O F M S S P A S T I C I T Y ?

* based on a price of £3752 for three 90-spray vials3 and a median dosage of 4 sprays per day4 Date of preparation: October 2012 Job code: L.GB.10.2012.0713

INDEPENDENT THINKING

am INC Research

am 1 in 2 million I was told that I was hard to fi nd, that there’s not many people in the world with my disease. So when they asked me about taking part in a study to understand my condition a bit better, I said yes. Because they made me feel like I could help, like I was needed. And that made me feel part of something much bigger.

To see how we can help you feel more connected, view our fi lm at incresearch.com

Specialist therapeutic expertise in Europe

Oncology

Sites need motivating

to effi ciently handle the

intensive data collection

and safety monitoring

involved in oncology trials.

With dedicated contacts

in each of Europe’s key

countries for anti-cancer

drug development, we

make sure your sites have

all the support they need.

Central Nervous

System

CNS studies often involve

tricky patient populations

and subjective effi cacy

measures. We work

closely with CNS research

communities to make

sure this isn’t a problem

for you. Our peer-to-peer

relationships help us

connect you with patients

who are the best fi t for

your studies, and our

site-training programs

make sure your studies

consistently generate

high-quality data.

Cardiovascular and

Endocrinology

If you’re looking for a

CRO to deliver large,

long-term, multinational

endpoint studies, we’ll

happily discuss what our

experience could do for

you: We’ve generated

evidence to support

approval of a wide range

of novel therapeutics

and medical devices

across cardiovascular

and endocrinology

indications. On the other

end of the spectrum,

our rare disease team

and special population

support units can make

sure you fi nd and keep

the right patients for

studies in rare endocrine

conditions.

General Medicine

We have a large enough

group in general medicine

to be able to structure

entire operational

teams according to your

needs. So if you want

CRAs who’ve supported

investigative sites

in gastroenterology,

immunology or

dermatology trials, or

project managers with

decades of experience

running studies in

infectious diseases, we

can make it happen.

Ophthalmology

With experience

covering a huge range

of ocular disorders

and side effects,

we’re used to creating

ophthalmic models

to assess endpoints

for novel ophthalmic

agents and biomarkers.

If appropriate, we’ll

happily do that for

you too, gathering our

therapeutic experts

from cross-disciplinary

areas so that we can help

your ophthalmic studies

exceed your goals.

Medical Devices and

diagnostics

With over 330 medical device

and diagnostics studies

under our belt, we know how

to secure approval in this

area. We’ll handle anything

from pre-IDE activities,

safety/performance dossier

preparation, pre-IDE review

and 510(k) processes,

IDA/PMA approvals, CE

mark registration and

2010 EU IVD regulation

application, to implementing

GHTF device and diagnostics

guidance for you.

am in Europe

2

1

4

Scan here to watch the fi lm

Scan here to view the site

© PM

Group 2010. A

ll rights reserved.

45

PROFILELANGLAND


FOLLOW US AT


Address

Telephone

Fax

Email

Website


Established

Status

Number of staff


Geographical status



Rx Awards 2013

CLIO Awards 2013

Global Awards 2013

Epica Awards 2013

PM Awards 2013

PMEA Awards 2013

AWARDS


AGENCY INFORMATION


Abbott

AbbVie

Allergan

ALK

Astellas

Bayer

BlissBritish Skin FoundationCelgene

eClinical Health Eli Lilly Gilead IDIS INC Research LEO Pharmaceuticals NSPCC Otsuka Pfi zer Sebastian’s Action Trust Shire Synexus

CLIENTS PRODUCTS

LANGLANDABOUT US

© PM

Group 2010. A

ll rights reserved.

See the

showreel

Download Layar from the App Store or Google Play, hold smartphone

or tablet over page, and play.

Obsessive

Compulsive©

PMG

roup 2010. All rights reserved.

47

PROFILE LIFE



Address

Telephone

Fax

Email

Website

The core team

Established

Status

Number of staff


Geographical status


PharmaTimes Marketer of the Year

The Rx Club Awards

eyeforpharma Mobile Health Competition

IPA Best of Health Awards


AWARDS

AGENCY INFORMATION


A Menarini

Abbott

Abbott global

Actis

Alcon

AstraZeneca

Biosimilar company global

Celgene global

Cell Therapeutics Incorporated global

Clinigen

Ferring

Galderma

Galen

Genus

Novo Nordisk

Proteus

Rayner

Vertex global

Wockhardt

CLIENTS PRODUCTS

LIFEWE LIKE TO DO THINGS RIGHT…


FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.

49

PROFILE M

JL



Address

Telephone

Email

Website

The team

Established

Status

Number of staff




The Rx Club (New York) Awards

VMA Advertising Awards

PM Society Awards

IPA Best of Health

AWARDS

AGENCY INFORMATION

M




Chiesi

Consilient Health

Dermal Laboratories


Grünenthal

GSK

Leo Pharma A/S

Lundbeck

MSD Animal Health

Menarini

Norgine Pharmaceuticals

Tillotts

United Therapeutics

Vetoquinol

CLIENTS PRODUCTS

MJLClients who’ve found out how hard we work at keeping their brands performing tend to stay with us. That’s why we have some of the longest client relationships in the business.

To find out more, contact Justin McCarthy or Phil Ledger on 01462 431 477

FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.

51

PROFILE PAN



Address

Telephone

Email

Website


The team

Established

Corporate status


Number of staff

Geographical status


Global Awards

PMEA


PM Society Digital Awards

Pharma Times

RECENT AWARDS

AGENCY INFORMATION

M

M



PANINFLUENTIAL CREATIVITY...

FOLLOW US AT

Amgen (EU, UK)

Amgen-GSK (EU, UK, RoI)

Astellas Pharma

GSK (GlaxoSmithKline)

INC Research (global)

Ipsen (UK)

MSD (UK)

Roche (UK)

Takeda

Teva (UK)

Tissue Therapies (global)

To Health

UCB (UK)

Warner Chilcott (UK)

CLIENTS PRODUCTS

© PM

Group 2010. A

ll rights reserved.

53

PROFILE PUBLICIS LIFE BRANDS RESOLUTE


FOLLOW US AT


Address

Telephone

Email

Website

The team

Established

Corporate status


Number of staff


Geographical status


AGENCY INFORMATION


AWARDS

CLIENTS

WHY US?

PUBLICIS LIFE BRANDS RESOLUTE

M

Strategy

Communications

OUR DIGITAL OFFERING


2014 PM Awards

2013 The Rx Club

Cannes Lions

Creative Circle Awards

IPA Best of Health

2012 Clio Healthcare Awards

Global Awards

The RX Club

PM Society Digital Media Awards

IPA Best of Health

AstraZeneca

BMS


Merial

Novartis

Omron

Pfizer

Sanofi

Sanofi Pasteur

Takeda

Publicis Life BrandsResolute

© PM

Group 2010. A

ll rights reserved.

Visit our website and join our book club

www.sevenstones.co.uk

Thinking long term: Corporate campaign for Celgene

Thinking long term for patients with multiple myeloma

We believe that multiple myeloma shouldn’t stop him from starting


We believe that multiple myeloma shouldn’t stop him from starting


We believe that multiple myeloma shouldn’t stop her from starting

The Dr Falk Way: Dr Falk portfolio

Corporate identity: DKPT fitness

They wouldn’t know: Simponi for MSD

Now Alfi e doesn’t see her RA

monthly

Simponi once a month. Because life is everyday.Prescribing information may be found on the reverse

Now the passengers on the No.43 don’t notice her PsA monthly


Now the students don’t see his AS

monthly


DAVID KINGSBURY

PERSONAL TRAINER

INNERWORKING OUT

© PM

Group 2010. A

ll rights reserved.

55

PROFILESEVEN STONES



Address

Telephone

Fax

Email

Websites


The team

Established

Corporate status


Number of staff


Geographical status


IPA Awards

PM Society Awards

PMEA

AWARDS

AGENCY INFORMATION

Advertising

Digital communications

Brand Building

Design


AbbVie

Bayer

CareFusion

Celgene

DKPT

Dr Falk

Galderma

GE Healthcare

Gilead Sciences

MSD

MyZone

Nestlé

Shire

Urgo

Wockhardt

CLIENTS PRODUCTS

SEVEN STONESPROFILE

© PM

Group 2010. A

ll rights reserved.

Swordfish Advertising Limited St Thomas Court Thomas Lane Bristol BS1 6JG Web: www.swordfishadvertising.co.uk

GI V E YOUR NE X T C A MPA IGN A H A PP Y ENDING.

© PM

Group 2010. A

ll rights reserved.

57

PROFILE SW

ORDFISH ADVERTISING



Address

Telephone

Fax

Email

Website

Established

Status

Number of staff


Geographical status



AWARDS

AGENCY INFORMATION



Archimedes Pharma

Chiesi

Danone

Department of Health South West

Ferring

Genzyme

Hospira

Martindale Pharma

Mitsubishi Pharma Europe

Norgine ®,

Nuffield Health Hospitals

Probiotics International

Sandoz

Shire Pharmaceuticals

Takeda UK

CLIENTS PRODUCTS

SWORDFISH ADVERTISINGINSPIRING GREAT IDEAS

Above the line advertising:

Below the line advertising:

Digital/eMarketing:

M

Design:

Moving images:

Strategic planning:

Event management:

Training:

Project level:

FOLLOW US AT

© PM

Group 2010. A

ll rights reserved.


INDE

X W

HO’S

WHO

WHO’S WHONAME COMPANY PAGES

Nick Bartlett inVentiv Health Communications 42-43

Phil Bartlett CDM London 26-27

Chris Bartley Havas Life Medicom 38-39

Ben Blackmore bmore creative 24-25

Nick Broughton HAVAS LYNX 40-41

Zuleika Burnett Havas Life Medicom 38-39

Olly Caporn CDM London 26-27

Philip Chin Langland 44-45

David Corran Dark Horse Agency 28-29

Gerry Crawford H4B London 32-33

Niki Crossley Halesway 34-35

Neil Dickinson Dice 30-31

Michel Dubery inVentiv Health Communications 42-43

Andrew Durkan Havas Life Medicom 38-39

Sarah Dyson Havas Life Medicom 38-39

Justin Earl Seven Stones 54-55

Phil Eaton MJL 48-49

Steve Eckersley bmore creative 24-25

Martin Ellis Havas Life Medicom 38-39

Rebecca Gittins Hanson Zandi 36-37

Paul Haley bmore creative 24-25

Richard Hart inVentiv Health Communications 42-43

Gaynor Hayburn Havas Life Medicom 38-39

Ian Howard MJL 48-49

Megan Howard Publicis Life Brands Resolute 52-53

David Hunt HAVAS LYNX 40-41

Matt Joyce CDM London 26-27

David Kane inVentiv Health Communications 42-43

Louise Knapp Dice 30-31

Anna Korving Publicis Life Brands Resolute 52-53

Juliet La Marque Life 46-47

Phil Ledger MJL 48-49

Matt Leeming Life 46-47

Jon Linscott PAN 50-51

Reg Manser Life 46-47

Tom Mardling Dark Horse Agency 28-29

© PM

Group 2010. A

ll rights reserved.

59

INDEX W

HO’S WHO


NAME COMPANY PAGES

Stephen Martin Life 46-47

Angela McBride Life 46-47

Justin McCarthy MJL 48-49

Sarah Merritt Havas Life Medicom 38-39

Gary Monk HAVAS LYNX 40-41

Steve Nicholas HAVAS LYNX 40-41

Patrick Norrie inVentiv Health Communications 42-43

Arron O’Hare PAN 50-51

Dominic Owens Seven Stones 54-55

Neil Padgett Halesway 34-35

Stephen Page Havas Life Medicom 38-39

Stephanie Parsons Dark Horse Agency 28-29

Shaheed Peera Publicis Life Brands Resolute 52-53

Alex Perryman Seven Stones 54-55

Kush Rach bmore creative 24-25

Shelley Rahe CDM London 26-27

Francesco Raimo Life 46-47

Liz Rawlingson Halesway 34-35

Susan Ryan Dark Horse Agency 28-29

Brad Sellars H4B London 32-33

Alan Smith Dark Horse Agency 28-29

Jenny Sowerby Dice 30-31

Kate Spencer Langland 44-45

Manolis Stalford Havas Life Medicom 38-39

Julia Straker PAN 50-51

Ben Theophanous inVentiv Health Communications 42-43

Ilya Todd Swordfish Advertising 56-57

Sarah Verhoeff PAN 50-51

Jon Vernon HAVAS LYNX 40-41

Susan Walkley Havas Life Medicom 38-39

Catherine Warne PAN 50-51

Jack Westley Dark Horse Agency 28-29

David Whittingham HAVAS LYNX 40-41

Emily Wigginton Life 46-47

Jonathan Yuill H4B London 32-33

Elaine Zandi Hanson Zandi 36-37

© PM

Group 2010. A

ll rights reserved.


INDE

X OF

CLI

ENTS

Abbott


Abbott Vascular

AbbVie

Actelion

Actis

Alcon

Alexion

ALK

Allergan

Allergy Therapeutics

Almirall

Amgen

Archimedes Pharma

Astellas

AstraZeneca

Baxter

Bayer

Biogen Idec

Biosimilar company global

Bliss

BMS (Bristol-Myers Squibb)


BPL

Bridge to Life

Britannia

British Skin Foundation

CareFusion

Celgene

Cell Therapeutics Incorporated Global

Chiesi

Clinigen

Consilient Health

CSL Behring

Daiichi Sankyo

Daniels Healthcare

Danone

Department of Health South West

Derma UK

Dermal Laboratories

DKPT

Dr Falk

Dreamskin

eClinical Health

Edwards Lifescience

Eisai

Elanco

Ethicon

EUSA Pharma

Ferring

Galderma

Galen

GE Healthcare

Gedeon Richter

Genus

Genzyme

Gilead

Grünenthal

GSK (GlaxoSmithKline)

Hospira

Idis

Immatics

INC Research

Internis

Ipsen

INDEX OF CLIENTS

© PM

Group 2010. A

ll rights reserved.

61

INDEX OF CLIENTS


Janssen EMEA

Janssen-Cilag

Johnson & Johnson

June Medical

Kowa

Leo Pharma

Lilly

Lundbeck

Mallinckrodt

Malvern

Martindale

Medtronic

Menarini

Merck

Merck Serono

Merial

Metrasens

Mitovie

Mitsubishi Pharma Europe

MSD

MyZone

Napp

Nestlé

Norgine Pharmaceuticals

Novartis

Novo Nordisk

NSPCC

Nuffield Health Hospitals

Nutricia

Omron

Orphan Europe

Ortho Clinical Diagnostics

Otsuka

Owen Mumford

Penn Pharma

Pfizer

Probiotics International

ProStrakan

Proteus

Rayner

Reckitt Benckiser

Roche

Sage Healthcare

Sandoz

Sanofi

Sanofi Pasteur

Sealed Air

Sebastian’s Action Trust

Shire

Siemens

Sigma Tau

Sirtex Global and Europe

Smith & Nephew

Smiths Medical Europe

Synexus

Takeda

Teva

Tillotts

Tissue Therapies

To Health

UCB

United Therapeutics

Urgo

Vertex global

Vetoquinol

Warner Chilcott

Wockhardt

© PM

Group 2010. A

ll rights reserved.

63

INDEX OF PRODUCTS/CAM

PAIGNS


Abbott Nutrition portfolio

Accrete D3

Adcetris

Adcirca

Adempas

Adenuric

Adoport

AdreView

Advagraf

Alaris

Alimta

AmBisome

Anaemia

Analyser range

Animal health

Antibiotics

Aranesp

Asacol

Atimos

Aurum suppositories

Avamys

Avanz

Avonex

Azarga

Beizer UW

Betaferon

Betmiga

Binocrit

Biopharm

Biosurgery

Blood glucose monitoring

Branding

Budenofalk

Caffeine suppositories

Calcichew

Calfovit

Cancer immunotherapy

Cardiovascular

Cayston

Cervarix

Cetraben portfolio

Charity

ChloraPrep

Cimzia

Clave

Clenil

Clinical trial marketing & promotions

Clinigen GAP

CoaguChek

Coated Vicryl Plus

Cobas laboratory analysers

Condoms

Contraception

Corporate

Corporate EPD

Creon

Critical care

DAP

DaTSCAN

Dermabond advanced

Dermatology

DesmoMelt

Diagnostic imaging

Difmetre

Dovobet

Dreamskin Health Garments

DryTec

DuoDopa

DuoTrav

Dysport

Elaprase

Elvanse (Market Access)

Endovascular

Epiduo

Estring

Etrivex

Exembol (HIT II Therapy)

INDEX OF PRODUCTS/CAMPAIGNS

© PM

Group 2010. A

ll rights reserved.


INDE

X OF

PRO

DUCT

S/CA

MPA

IGNS

Eylea

Ezetrol

Fampyra

Femoston

Ferroguard

Fertility portfolio

Fitness

Fostair

Franchise marketing

FreeStyle range

Fultium D3

Gadovist

Ganfort

Gastroenterology

Gemstar

Generics

Gopten

Gout patient awareness

Grazax

Growth portfolio

Haemophilia

Helius

Hidrasec e-detail programme

Homecare

Hospital specialty products

HRT

Humira

Immunology portfolio

Inborn errors of metabolism

Infant feeding

Invita D3

Iressa

Isoptin

Januvia

Jext

Kalydeco

Keppra

Ketofen

Kogenate

Lamictal

Lenses portfolio

Lepicol

Lifeshield TKO

Lonquex

Lubricants

Lumigan

Magnevist

Market access (Elvanse)

MaxPlus

MedRad

Mezavant

Mezolar Matrix

Mimpara

Modigraf

Mometasone

Monocryl Plus

Movicol

MyoView

Nephrology (education)

Neutropenia

New product

Nexavar

Nipent

Norditropin

Normosang

Novo corporate diabetes programme

Octasa

Omacor

Omnipaque

Omniscan

Omnitrope

Online education

Ophthalmics

Ophthalmology

Optison

Oralvac

PAH portfolio

INDEX OF PRODUCTS/CAMPAIGNS

© PM

Group 2010. A

ll rights reserved.

65

INDEX OF PRODUCTS/CAM

PAIGNS


Pain portfolio

Palexia

Paracetamol suppositories

PDS plus

Physeptone

Physiotens

Pixuvri

Plum-A

Pollinex

Pollinex Quattro

Primovist

Prolia

Prostap

Public health breastfeeding awareness

Ranexa

Remodulin

Requip

Resolor (international training)

Revlimid

Rheumatology

Rhophylac

Ribomustin

Salofalk

Sativex

Sealed Air medical applications

Selexid

Self-medication devices

Selincro

Setofilm

Simponi

SIR-Spheres

SLITone ultra

SMA

Somatuline

Specials

Stivarga

Stroke prevention in atrial fibrillation

Structural heart

Synagis

Systane portfolio

Targaxan

Tarka

Testim

Teveten

Thermachoice III

Tracleer

Travatan

Trustsaver product portfolio

Tysabri

Tyverb

Urea cycle disorders

Ursofalk

Vaccines

Versapoint II

Versascope

Vesicare

Vesomni

Vibativ

Vicryl plus (coated)

Vidaza

Visipaque

Vitiq

VitroGro

Volibris

Votrient

VTE prophylaxis

Wound dressings

Woundcare

Xagrid

Xgeva

Xifaxan

Xifaxanta

Xofigo

Xtandi

Zarzio

Zemplar

ZomaJet

© PM

Group 2010. A

ll rights reserved.

the directory of advertising, branding, creative and digital agencies in healthcare 43www.pmlive.com/thedirectory

Profiles of agencies are compiled from information received from companies themselves. While every effort has been made to ensure that the information in this publication is correct, the publishers accept no liability for any loss incurred in any way whatsoever by any person relying solely on the information contained herein. To the best of our knowledge and belief, however, the facts stated are accurate as known at the time of compilation.

ADVERTISERS INDEX & ACKNOWLEDGEMENTS

ADVERTISERS INDEX

The Directory of Advertising, Branding, Creative and Digital Agencies

ACKNOWLEDGMENTS

ADV

ERTI

SERS

INDE

X &

ACKN

OWLE

DGEM

ENTS

The Directory Volume 44October 2014 to

March 2015 will be published in October 2014

bmore creative 24-25

CDM London 26-27

Dark Horse Agency 28-29

Dice 30-31

H4B London 32-33

Halesway 34-35

Hanson Zandi 36-37

Havas Life Medicom 38-39

HAVAS LYNX 40-41

inVentiv Health Communications 42-43

Langland 44-45

Life 46-47

MJL 48-49

PAN 50-51

Publicis Life Brands Resolute 52-53

Seven Stones 54-55

Swordfish Advertising 56-57

COMPANY PAGES

66

© PM

Group 2010. A

ll rights reserved.

www.pmlive.com/digital_handbook

For easy access to our full range of unrivalled digital pharma coverage

DIGITAL INSPIRATION FOR PHARMA ON MOBILE, SOCIAL MEDIA, STRATEGY,

BEST PRACTICE, REGULATIONS AND MORE

© PM

Group 2010. A

ll rights reserved.

To see the video trailer, download Layar from the App Store or Google Play, and hold your smartphone or tablet over the image above to play.

Fight Bac campaign for GaldermaBy: Life

www.pmlive.com/thegallery

A visual showcase of agency creativity and campaigns

gallery

Go to this online portfolio to track campaigns by agency, client, product or therapy area

Healthcare agencies – be there to be seenContact [email protected] to get your work uploaded

It only costs you an email

© PM

Group 2010. A

ll rights reserved.

Time saving

Documents

Transcript of Time saving